A new study published in the journal of PloS One showed that although reoperative therapy with evolocumab with rosuvastatin ...

- Reduced inflammation at the site of myocardial infarction and improved heart function demonstrated. Novel therapy to modulate immune response with apoptotic cell-derived nanovesicles. Myocardial ...

New evidence reveals adult human hearts can regrow muscle cells after myocardial infarction, opening new possibilities for ...

Acute myocardial infarction (AMI) remains a leading cause of morbidity and mortality worldwide, primarily resulting from an abrupt coronary artery occlusion that deprives myocardial tissue of oxygen.

Credit: Getty Images A discussion of the use of beta-blocker therapy following AMI, with Christopher Granger, MD, Gregg Fonarow, MD, and Carlin S Long, MD. Beta blockers have long been included in the ...

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Myocardial infarction (MI) triggers adverse remodeling mechanisms, thus leading to heart failure. Since ...

ST-segment myocardial infarction (STEMI) causes significant morbidity and mortality, with infarct size being the primary predictor of clinical outcome. Given imaging evidence that early IV metoprolol ...

ESTERO, FLORIDA / ACCESS Newswire / September 3, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) (“Aspire” or the “Company”), developer of a multi-faceted patent-pending drug delivery technology, ...

MULHOUSE, France, and SUNNYVALE, Calif., July 08, 2024 (GLOBE NEWSWIRE) -- CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and BioCardia, Inc.

Advanced CKD was linked to a higher likelihood of both fatal and non-fatal adverse outcomes after acute myocardial infarction treatment. Patients with advanced chronic kidney disease (ACKD) with acute ...